DMAA

Drugs Made In America Acquisition Corp. Rights

NASDAQ: DMAAR · ·

$0.09

-3.78% today

Updated 2026-04-29

Market cap

$1.73M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$—

Dividend yield

—

52W range

$0 – $0

Volume

0.2M

Market cap

$1.73M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$—

Dividend yield

—

52W range

$0 – $0

Volume

0.2M

Drugs Made In America Acquisition Corp. Rights (DMAAR) Financial Forecast & Price Target 2030

Revenue-driven projection model with historical context.

Price target summary

Current price

$0.09

12-Month target

—

2030 Target

—

Intrinsic (DCF)

—

Financial forecast

Metric
Revenue
EPS

CAGR applied: — (capped 20%) · P/E: 25.00x (capped 25x) · Margin: 0.00%

Methodology

CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.